

# Adil I Daud

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5562689/adil-i-daud-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

235  
papers

28,286  
citations

63  
h-index

167  
g-index

255  
ext. papers

33,724  
ext. citations

8.1  
avg. IF

6.52  
L-index

#	Paper	IF	Citations
235	TCR-sequencing in cancer and autoimmunity: barcodes and beyond.. <i>Trends in Immunology</i> , <b>2022</b> ,	14.4	1
234	Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of plasmid CXCL9 synergizes with plasmid IL-12 therapy to elicit robust anti-tumor immunity.. <i>Molecular Therapy - Oncolytics</i> , <b>2022</b> , 25, 174-188	6.4	0
233	Intratumoral therapies and in-situ vaccination for melanoma.. <i>Human Vaccines and Immunotherapeutics</i> , <b>2022</b> , 18, 1890512	4.4	1
232	Immunotherapy in Melanoma and Merkel Cell Cancer <b>2022</b> , 709-718		
231	Discovering dominant tumor immune archetypes in a pan-cancer census.. <i>Cell</i> , <b>2021</b> ,	56.2	10
230	Single-cell analyses identify circulating anti-tumor CD8 T cells and markers for their enrichment. <i>Journal of Experimental Medicine</i> , <b>2021</b> , 218,	16.6	18
229	Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma <b>2021</b> , 9,		10
228	The Liver-Immunity Nexus and Cancer Immunotherapy. <i>Clinical Cancer Research</i> , <b>2021</b> ,	12.9	6
227	The State of Melanoma: Emergent Challenges and Opportunities. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 2678-2697	12.9	11
226	Response to PD-1 Immunotherapy in Metastatic Spiradenocarcinoma.. <i>JCO Precision Oncology</i> , <b>2021</b> , 5, 340-343	3.6	1
225	Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. <i>European Journal of Cancer</i> , <b>2021</b> , 144, 182-191	7.5	23
224	Tissue-specific Tregs in cancer metastasis: opportunities for precision immunotherapy. <i>Cellular and Molecular Immunology</i> , <b>2021</b> ,	15.4	5
223	Layilin Anchors Regulatory T Cells in Skin. <i>Journal of Immunology</i> , <b>2021</b> , 207, 1763-1775	5.3	0
222	Should Sentinel Lymph Node Biopsy Status Guide Adjuvant Radiation Therapy in Patients With Merkel Cell Carcinoma?. <i>Advances in Radiation Oncology</i> , <b>2021</b> , 6, 100764	3.3	
221	Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. <i>European Journal of Cancer</i> , <b>2021</b> , 157, 391-402	7.5	2
220	Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 2827-2837	12.9	43
219	ASO Author Reflections: Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma. <i>Annals of Surgical Oncology</i> , <b>2020</b> , 27, 4131-4132	3.1	

218	Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma. <i>Annals of Surgical Oncology</i> , <b>2020</b> , 27, 4122-4130	3.1	5
217	Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients. <i>Annals of Oncology</i> , <b>2020</b> , 31, 532-540	10.3	49
216	Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in -Mutant Melanoma. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 46-53	12.9	21
215	Prognostic Biomarkers for Melanoma Immunotherapy. <i>Current Oncology Reports</i> , <b>2020</b> , 22, 25	6.3	8
214	Intratumoral Plasmid IL12 Electroporation Therapy in Patients with Advanced Melanoma Induces Systemic and Intratumoral T-cell Responses. <i>Cancer Immunology Research</i> , <b>2020</b> , 8, 246-254	12.5	27
213	Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis. <i>Science Immunology</i> , <b>2020</b> , 5,	28	48
212	Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial. <i>Nature Medicine</i> , <b>2020</b> , 26, 1564-1568	50.5	27
211	Treatment of Metastatic Melanoma With Leptomeningeal Disease Using Intrathecal Immunotherapy. <i>JCO Oncology Practice</i> , <b>2020</b> , 16, 757-759	2.3	5
210	Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials. <i>JAMA Oncology</i> , <b>2020</b> , 6, 1256-1264	12.4	27
209	Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer. <i>Nature Communications</i> , <b>2020</b> , 11, 3584	17.4	41
208	Layilin augments integrin activation to promote antitumor immunity. <i>Journal of Experimental Medicine</i> , <b>2020</b> , 217,	16.6	9
207	Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell Carcinoma. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 598-607	12.9	34
206	An analysis of genetic heterogeneity in untreated cancers. <i>Nature Reviews Cancer</i> , <b>2019</b> , 19, 639-650	31.3	71
205	Clonal Deletion of Tumor-Specific T Cells by Interferon- $\gamma$ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade. <i>Immunity</i> , <b>2019</b> , 50, 477-492.e8	32.3	56
204	Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. <i>Annals of Oncology</i> , <b>2019</b> , 30, 582-588	10.3	325
203	Intratumoral and Combination Therapy in Melanoma and Other Skin Cancers. <i>American Journal of Clinical Dermatology</i> , <b>2019</b> , 20, 781-796	7.1	5
202	Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4 T Cell Immunity. <i>Cell</i> , <b>2019</b> , 177, 556-571.e16	56.2	195
201	Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 693-702	2.2	188

200	A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600 mutant advanced melanoma. <i>Pigment Cell and Melanoma Research</i> , <b>2019</b> , 32, 603-606	4.5	11
199	Combinatorial Approach to Treatment of Melanoma <b>2019</b> , 687-697		
198	Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. <i>Lancet Oncology</i> , <b>2019</b> , 20, 1239-1251	21.7	425
197	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology</i> , <b>2019</b> , 20, e378-e389	21.7	88
196	Regulatory T cells use arginase 2 to enhance their metabolic fitness in tissues. <i>JCI Insight</i> , <b>2019</b> , 4,	9.9	27
195	PTCH1 Mutation in a Patient With Metastatic Undifferentiated Carcinoma With Clear Cell Change. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2019</b> , 17, 778-783	7.3	5
194	The gut microbiota and immune checkpoint inhibitors. <i>Human Vaccines and Immunotherapeutics</i> , <b>2018</b> , 14, 2178-2182	4.4	22
193	Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 4960-4967	12.9	142
192	Revisiting RECIST: the case of treatment beyond progression. <i>Lancet Oncology</i> , <b>2018</b> , 19, 157-159	21.7	2
191	Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma. <i>Pigment Cell and Melanoma Research</i> , <b>2018</b> , 31, 110-114	4.5	28
190	In-field and abscopal response after short-course radiation therapy in patients with metastatic Merkel cell carcinoma progressing on PD-1 checkpoint blockade: a case series <b>2018</b> , 6, 43		28
189	The lincRNA MIRAT binds to IQGAP1 and modulates the MAPK pathway in NRAS mutant melanoma. <i>Scientific Reports</i> , <b>2018</b> , 8, 10902	4.9	12
188	Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 5250-5260	12.9	65
187	Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial. <i>European Journal of Cancer</i> , <b>2018</b> , 101, 236-243	7.5	59
186	Current Immunotherapy of Melanoma <b>2018</b> , 567-576		
185	Negative but not futile: MAGE-A3 immunotherapeutic for melanoma. <i>Lancet Oncology</i> , <b>2018</b> , 19, 852-853	21.7	6
184	4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 9503-9503	2.2	60
183	Epacadostat plus nivolumab for advanced melanoma: Updated phase 2 results of the ECHO-204 study.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 9511-9511	2.2	29

182	5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 9516-9516	2.2	24
181	Melanocytic Neoplasms, Introduction. <i>Seminars in Cutaneous Medicine and Surgery</i> , <b>2018</b> , 37, 87	1.4	13
180	Combinatorial Approach to Treatment of Melanoma <b>2018</b> , 1-11		
179	Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III. <i>European Journal of Cancer</i> , <b>2018</b> , 91, 168-170	7.5	23
178	Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 667-673	2.2	138
177	Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 383-390	2.2	273
176	Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1668-1674	2.2	210
175	Cytokines, Chemokines, and Other Biomarkers of Response for Checkpoint Inhibitor Therapy in Skin Cancer. <i>Frontiers in Medicine</i> , <b>2018</b> , 5, 351	4.9	37
174	Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN- $\gamma$ and IL-12. <i>Immunity</i> , <b>2018</b> , 49, 1148-1161.e7	32.3	352
173	Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. <i>British Journal of Cancer</i> , <b>2018</b> , 119, 670-674	8.7	60
172	A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. <i>Nature Medicine</i> , <b>2018</b> , 24, 1178-1191	50.5	404
171	Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma. <i>British Journal of Cancer</i> , <b>2017</b> , 116, 432-440	8.7	43
170	Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients. <i>Journal of Hematology and Oncology</i> , <b>2017</b> , 10, 3	22.4	35
169	Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. <i>Cancer Immunology Research</i> , <b>2017</b> , 5, 417-424	12.5	241
168	Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial. <i>Annals of Oncology</i> , <b>2017</b> , 28, 1380-1387	10.3	85
167	Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy. <i>British Journal of Cancer</i> , <b>2017</b> , 116, 1141-1147	8.7	80
166	Melanoma treatment with intratumoral electroporation of tavokinogene telseplasmid (pIL-12, tavokinogene telseplasmid). <i>Immunotherapy</i> , <b>2017</b> , 9, 1309-1321	3.8	35
165	Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program. <i>Journal of Immunotherapy</i> , <b>2017</b> , 40, 334-340	5	15

164	Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours. <i>European Journal of Cancer</i> , <b>2017</b> , 86, 296-304	7.5	51
163	Inhibitors of Cytotoxic T Lymphocyte Antigen 4 and Programmed Death 1/Programmed Death 1 Ligand for Metastatic Melanoma, Dual Versus Monotherapy-Summary of Advances and Future Directions for Studying These Drugs. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2017</b> , 23, 3-9	2.2	5
162	Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). <i>Lancet, The</i> , <b>2017</b> , 390, 1853-1862	4.0	703
161	Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma. <i>Oncologist</i> , <b>2017</b> , 22, 823-833	5.7	51
160	Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. <i>European Journal of Cancer</i> , <b>2017</b> , 86, 37-45	7.5	106
159	Melanotic Schwannoma. <i>AJSP Review and Reports</i> , <b>2017</b> , 22, 161-163	0	
158	Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy. <i>JCI Insight</i> , <b>2017</b> , 2,	9.9	44
157	Epacadostat plus nivolumab in patients with advanced solid tumors: Preliminary phase I/II results of ECHO-204.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3003-3003	2.2	58
156	Relationship between liver metastases and PD-1 blockade in melanoma.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3072-3072	2.2	3
155	Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 9504-9504	2.2	40
154	Five-year overall survival (OS) update from a phase II, open-label trial of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E mutant unresectable or metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 9505-9505	2.2	6
153	Final results of a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab combination treatment in patients with stage IIIB-IV unresectable or metastatic melanoma.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 9510-9510	2.2	29
152	Quantitative spatial profiling of PD-1/PD-L1 interaction and HLA-DR/IDO1 to predict outcomes to anti-PD-1 in metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 9517-9517	2.2	2
151	Phase 1b/2 trial of ribociclib+binimetinib in metastatic NRAS-mutant melanoma: Safety, efficacy, and recommended phase 2 dose (RP2D).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 9519-9519	2.2	24
150	Sexual activity and function in male cancer patients receiving targeted an immune therapies.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e21594-e21594	2.2	1
149	Phase 1 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints PD-1 and VISTA, in patients (pts) with advanced solid tumor or lymphomas.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, TPS3099-TPS3099	2.2	16
148	Immune monitoring outcomes of patients with stage III/IV melanoma treated with a combination of pembrolizumab and intratumoral plasmid interleukin 12 (pIL-12).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 78-78	2.2	1
147	Patient attitudes toward oncofertility care in male cancer patients receiving targeted and immune therapies.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e21593-e21593	2.2	

146	Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. <i>Cancer</i> , <b>2016</b> , 122, 3344-3353	6.4	199
145	Emerging biomarkers as predictors to anti-PD1/PD-L1 therapies in advanced melanoma. <i>Immunotherapy</i> , <b>2016</b> , 8, 775-84	3.8	19
144	Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 871-8	2.2	206
143	Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1510-7	2.2	509
142	Abstract CT134: Intratumoral electroporation of plasmid IL-12 can prime response to anti-PD1/PD-L1 blockade in patients with Stage III/IV-M1a melanoma <b>2016</b> ,		4
141	Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 9503-9503	2.2	66
140	Efficacy and safety of programmed death receptor-1 (PD-1) blockade in metastatic uveal melanoma (UM).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 9507-9507	2.2	5
139	KEYNOTE-006 study of pembrolizumab (pembro) versus ipilimumab (ipi) for advanced melanoma: Efficacy by PD-L1 expression and line of therapy.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 9513-9513	2.2	8
138	Derivation and validation of a prediction scale for response to PD-1 monotherapy.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 9514-9514	2.2	2
137	Novel T cell exhaustion marker to predict monotherapy PD-1 compared to combination CTLA-4 and PD-1 response in melanoma.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 9520-9520	2.2	3
136	Preliminary results from phase II study of combination treatment with HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab in patients with stage IIIb, IIIc, or IV unresectable or metastatic melanoma.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 9543-9543	2.2	14
135	Correlation between metastatic site and response to anti-Programmed Death-1 (PD-1) agents in melanoma.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 9549-9549	2.2	9
134	Correlation between local 18F-fluorodeoxyglucose PET/CT and T cell exhaustion for predicting treatment response in patients with advanced melanoma treated with checkpoint inhibitor mono-therapy.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 11572-11572	2.2	
133	Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. <i>Journal of Clinical Investigation</i> , <b>2016</b> , 126, 3447-52	15.9	325
132	Part I: Checkpoint inhibitors in cancer therapy. <i>Immunotherapy</i> , <b>2016</b> , 8, 675-6	3.8	1
131	Increased FDG avidity in lymphoid tissue associated with response to combined immune checkpoint blockade <b>2016</b> , 4, 58		29
130	A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma. <i>Annals of Oncology</i> , <b>2016</b> , 27, 947-52	10.3	23
129	Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. <i>JAMA - Journal of the American Medical Association</i> , <b>2016</b> , 315, 1600-9	27.4	666

128	PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 2542-52	59.2	828
127	Pembrolizumab for melanoma- safety profile and future trends. <i>Expert Opinion on Drug Safety</i> , <b>2016</b> , 15, 727-9	4.1	8
126	Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. <i>European Journal of Cancer</i> , <b>2016</b> , 67, 46-54	7.5	54
125	Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4102-4109	2.2	400
124	A Review of Novel Intralesional Therapies for Melanoma, With an Emphasis on a Potential Combination Approach. <i>Oncology</i> , <b>2016</b> , 30, 442-3	1.8	2
123	Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1060-6	2.2	135
122	Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression. <i>JAMA Dermatology</i> , <b>2015</b> , 151, 1206-1212	5.1	305
121	The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial. <i>British Journal of Cancer</i> , <b>2015</b> , 112, 1326-31	8.7	23
120	Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 908-18	21.7	1151
119	Pembrolizumab versus Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , <b>2015</b> , 372, 2521-32	59.2	3792
118	Intratatumoral electroporation of plasmid interleukin-12: efficacy and biomarker analyses from a phase 2 study in melanoma (OMS-I100). <i>Journal of Translational Medicine</i> , <b>2015</b> , 13, O11	8.5	4
117	A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma. <i>Journal of Translational Medicine</i> , <b>2015</b> , 13, O5	8.5	20
116	The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date. <i>Drugs</i> , <b>2015</b> , 75, 563-75	12.1	16
115	Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4023-31	2.2	315
114	Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma. <i>Annals of Oncology</i> , <b>2015</b> , 26, 2173-9	10.3	53
113	Combined dabrafenib and trametinib therapy in metastatic melanoma and organ transplantation: Case report and review of the literature. <i>JAAD Case Reports</i> , <b>2015</b> , 1, S23-5	1.4	8
112	Nivolumab plus ipilimumab in the treatment of advanced melanoma. <i>Journal of Hematology and Oncology</i> , <b>2015</b> , 8, 123	22.4	38
111	Long-term overall survival from a phase I trial using intratumoral plasmid interleukin-12 with electroporation in patients with melanoma. <i>Journal of Translational Medicine</i> , <b>2015</b> , 13, O3	8.5	3



110	Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 4286-93	12.9	469
109	Current and Emerging Perspectives on Immunotherapy for Melanoma. <i>Seminars in Oncology</i> , <b>2015</b> , 42 Suppl 3, S3-S11	5.5	17
108	Future of combination therapy with dabrafenib and trametinib in metastatic melanoma. <i>Expert Opinion on Pharmacotherapy</i> , <b>2015</b> , 16, 2257-63	4	8
107	Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial. <i>Annals of Oncology</i> , <b>2015</b> , 26, 415-21	10.3	65
106	Abstract 2857: Metastatic site and response to pembrolizumab (anti-PD1 antibody) in melanoma <b>2015</b> ,		5
105	Atypical patterns of response in patients (pts) with metastatic melanoma treated with pembrolizumab (MK-3475) in KEYNOTE-001.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3000-3000	2.2	9
104	Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3001-3001	2.2	115
103	Efficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized comparison of pembrolizumab (pembro; MK-3475) versus chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) advanced melanoma (MEL).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3012-3012	2.2	17
102	Population pharmacokinetic (popPK) model of pembrolizumab (pembro; MK-3475) in patients (pts) treated in KEYNOTE-001 and KEYNOTE-002.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3058-3058	2.2	4
101	Model-based analysis of the relationship between pembrolizumab (MK-3475) exposure and efficacy in patients with advanced or metastatic melanoma.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3068-3068	2.2	3
100	Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 9005-9005	2.2	40
99	Clinical characteristics predictive of response to pembrolizumab in advanced melanoma.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 9031-9031	2.2	8
98	Patient-reported outcomes (PROs) in KEYNOTE-002, a randomized study of pembrolizumab vs chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) metastatic melanoma (MEL).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 9040-9040	2.2	2
97	Association of immune-related thyroid disorders with pembrolizumab (pembro, MK-3475) in patients (pts) with advanced melanoma treated in KEYNOTE-001.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 9050-9050	2.2	9
96	Deep profiling of tumor immune microenvironment (TME) with fluorescence activated cell sorting (FACS) in advanced melanoma.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 9012-9012	2.2	1
95	Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3697-704	2.2	158
94	Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma. <i>Journal of the American Academy of Dermatology</i> , <b>2014</b> , 71, 1102-1109.e1	4.5	58
93	Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. <i>Lancet, The</i> , <b>2014</b> , 384, 1109-17	40	1340

92	Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. <i>Cancer Cell</i> , <b>2014</b> , 26, 638-52	24.3	592
91	Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. <i>Lancet Oncology</i> , <b>2014</b> , 15, 954-65	21.7	197
90	Combinatorial approach to treatment of melanoma. <i>Hematology/Oncology Clinics of North America</i> , <b>2014</b> , 28, 601-12	3.1	3
89	Management of a patient with advanced BRAF-mutant melanoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2014</b> , 12, 315-9; quiz 319	7.3	1
88	Melanoma, version 4.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2014</b> , 12, 621-9	9.3	52
87	Patterns of response in patients with advanced melanoma treated with Pembrolizumab (MK-3475) and evaluation of immune-related response criteria (irRC) <b>2014</b> , 2,		6
86	PD-1 and PD-L1 antibodies for melanoma. <i>Human Vaccines and Immunotherapeutics</i> , <b>2014</b> , 10, 3111-6	4.4	41
85	Melanoma immunotherapy. <i>Cancer Biology and Therapy</i> , <b>2014</b> , 15, 665-74	4.6	54
84	The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics. <i>Journal of Clinical Pharmacology</i> , <b>2014</b> , 54, 368-74	2.9	32
83	Involution of eruptive melanocytic nevi on combination BRAF and MEK inhibitor therapy. <i>JAMA Dermatology</i> , <b>2014</b> , 150, 1209-12	5.1	18
82	A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2014</b> , 73, 103-11	3.5	44
81	Abstract CT104: Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma(MEL): Correlation of tumor PD-L1 expression with outcome <b>2014</b> ,		19
80	Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumab-refractory (IPI-R) and IPI-naive (IPI-N) melanoma (MEL).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3000-3000	2.2	9
79	Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3005-3005	3.3	47
78	Evaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3006-3006	2.2	20
77	Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3015-3015	2.2	17
76	Phase 1-2 trial of the BRAF inhibitor dabrafenib (D) plus MEK inhibitor trametinib (T) in BRAF V600 mutant colorectal cancer (CRC): Updated efficacy and biomarker analysis.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3517-3517	2.2	14
75	Metabolic tumor burden for prediction of overall survival following combined BRAF/MEK inhibition in patients with advanced BRAF mutant melanoma.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 9006-9006	2.2	2

74	Updated overall survival (OS) for BRF113220, a phase 1-2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D+T) in pts with BRAF V600 mutation-positive (+) metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 9010-9010	2.2	11
73	Systemic antitumor effect and clinical response in a phase 2 trial of intratumoral electroporation of plasmid interleukin-12 in patients with advanced melanoma.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 9025-9025	2.2	16
72	A phase I trial of BKM120 combined with vemurafenib in BRAFV600E/k mutant advanced melanoma.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 9101-9101	2.2	8
71	Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, LBA9000-LBA9000	2.2	32
70	Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. <i>New England Journal of Medicine</i> , <b>2013</b> , 369, 134-44	59.2	2661
69	Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2013</b> , 110, 4015-20	11.5	168
68	Reply to M.-E. Percival et al and L.B. Saltz. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2515-6	2.2	
67	Melanoma, version 2.2013: featured updates to the NCCN guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2013</b> , 11, 395-407	7.3	112
66	BKM120 combined with vemurafenib in vemurafenib-refractory BRAF mutant metastatic melanoma: Two cases.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, e20010-e20010	2.2	2
65	Phase I study of pazopanib (PAZ) in combination with PCI-24781 (PCI) in patients (pts) with metastatic solid tumors with new tumor proliferation imaging correlates in renal cell carcinoma (RCC) and sarcoma.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, TPS2623-TPS2623	2.2	
64	Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. <i>New England Journal of Medicine</i> , <b>2012</b> , 367, 1694-703	59.2	2048
63	Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma. <i>Expert Opinion on Biological Therapy</i> , <b>2012</b> , 12, 1087-99	5.4	21
62	Cutting edge in medical management of cutaneous oncology. <i>Seminars in Cutaneous Medicine and Surgery</i> , <b>2012</b> , 31, 140-9	1.4	6
61	Beyond BRAF in melanoma. <i>Current Topics in Microbiology and Immunology</i> , <b>2012</b> , 355, 99-117	3.3	11
60	Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 1092-100	12.9	61
59	Plasmid IL-12 electroporation in melanoma. <i>Human Vaccines and Immunotherapeutics</i> , <b>2012</b> , 8, 1734-8	4.4	29
58	Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma. <i>British Journal of Cancer</i> , <b>2012</b> , 106, 85-91	8.7	31
57	Melanoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2012</b> , 10, 366-400	7.3	53

56	A clinical and translational phase II trial of sequential axitinib and carboplatin/paclitaxel in advanced melanoma.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 8580-8580	2.2	
55	Tumor fistulization associated with targeted therapy: computed tomographic findings and clinical consequences. <i>Journal of Computer Assisted Tomography</i> , <b>2011</b> , 35, 86-90	2.2	18
54	An isolated Merkel cell carcinoma metastasis at a distant cutaneous site presenting as a second primary tumor. <i>Journal of Cutaneous Pathology</i> , <b>2011</b> , 38, 801-7	1.7	13
53	Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon $\alpha$ 2b in patients with resected high-risk melanoma. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2011</b> , 67, 657-66	3.5	20
52	Cutaneous melanoma: a model to study cancer metastasis. <i>Journal of Surgical Oncology</i> , <b>2011</b> , 103, 538-498	4.8	27
51	Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma. <i>Expert Opinion on Investigational Drugs</i> , <b>2011</b> , 20, 1565-74	5.9	23
50	Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 7765-75	12.9	36
49	Protein Kinase Inhibitors <b>2011</b> , 319-330		
48	Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma. <i>British Journal of Cancer</i> , <b>2010</b> , 103, 1548-53	8.7	16
47	Treatment of cutaneous melanoma: current approaches and future prospects. <i>Cancer Management and Research</i> , <b>2010</b> , 197	3.6	1
46	Implementation of a High-Dose Interleukin-2 Immunostimulation Biotherapy Program. <i>ICU Director</i> , <b>2010</b> , 1, 77-81		2
45	Changes in dendritic cell phenotype after a new high-dose weekly schedule of interleukin-2 therapy for kidney cancer and melanoma. <i>Journal of Immunotherapy</i> , <b>2010</b> , 33, 817-27	5	37
44	New horizons in melanoma treatment: targeting molecular pathways. <i>Ochsner Journal</i> , <b>2010</b> , 10, 93-8	1.5	1
43	Treatment of cutaneous melanoma: current approaches and future prospects. <i>Cancer Management and Research</i> , <b>2010</b> , 2, 197-211	3.6	29
42	Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 2823-30	2.2	456
41	Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 2479-87	12.9	68
40	A phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2009</b> , 63, 903-10	3.5	40
39	Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. <i>British Journal of Cancer</i> , <b>2009</b> , 101, 1044-50	8.7	126

38	Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 2488-96	12.9	120
37	Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma. <i>Melanoma Research</i> , <b>2009</b> , 19, 167-75	3.3	43
36	Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 5896-903	2.2	520
35	Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 5198-203	2.2	206
34	Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 3235-41	2.2	170
33	Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 8302-7	12.9	179
32	Activated stat-3 in melanoma. <i>Cancer Control</i> , <b>2008</b> , 15, 196-201	2.2	53
31	The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. <i>BMC Medical Genomics</i> , <b>2008</b> , 1, 13	3.7	367
30	State of the science 60th anniversary review: 60 Years of advances in cutaneous melanoma epidemiology, diagnosis, and treatment, as reported in the journal Cancer. <i>Cancer</i> , <b>2008</b> , 113, 1728-43	6.4	11
29	Melanoma Genomics—Techniques and Implications for Therapy. <i>Translational Medicine Series</i> , <b>2008</b> , 37-54		
28	The Src signaling pathway: a potential target in melanoma and other malignancies. <i>Expert Opinion on Therapeutic Targets</i> , <b>2007</b> , 11, 91-100	6.4	50
27	Down-regulation of pro-apoptotic genes is an early event in the progression of malignant melanoma. <i>Annals of Surgical Oncology</i> , <b>2007</b> , 14, 1416-23	3.1	17
26	Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 5855-61	12.9	86
25	Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 1979-85	2.2	187
24	Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. <i>Cancer Control</i> , <b>2007</b> , 14, 285-94	2.2	122
23	Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 4645-51	12.9	31
22	Evaluation of toxicity following electrically mediated interleukin-12 gene delivery in a B16 mouse melanoma model. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 3177-83	12.9	69
21	Overall and progression-free survival in metastatic melanoma: analysis of a single-institution database. <i>Cancer Control</i> , <b>2006</b> , 13, 211-7	2.2	20

20	Immunotherapy as part of a multidisciplinary approach to melanoma treatment. <i>Frontiers in Bioscience - Landmark</i> , <b>2006</b> , 11, 1-14	2.8	17
19	Vascular endothelial growth factor (VEGF) inhibitors in cancer therapy: an update. <i>Women's Oncology Review</i> , <b>2006</b> , 6, 127-136		
18	Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. <i>Cancer Research</i> , <b>2005</b> , 65, 3815-22	10.1	175
17	Current immunotherapy of melanoma. <i>Clinical and Applied Immunology Reviews</i> , <b>2005</b> , 5, 111-132		2
16	Cutaneous melanoma: prognostic factors. <i>Cancer Control</i> , <b>2005</b> , 12, 223-9	2.2	82
15	In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates. <i>Molecular Cancer Therapeutics</i> , <b>2005</b> , 4, 1993-2000	6.1	66
14	Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 3009-16	12.9	50
13	Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 8467-75	12.9	55
12	Uncommon manifestations of common malignancies: case 3. Malignant melanoma arising from a spinal nerve root. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 3194-5	2.2	13
11	Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. <i>Journal of Cellular Biochemistry</i> , <b>2004</b> , 92, 223-37	4.7	167
10	Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. <i>Oncogene</i> , <b>2002</b> , 21, 7001-10	9.2	353
9	A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. <i>Clinical Cancer Research</i> , <b>2002</b> , 8, 2505-11	12.9	298
8	New drugs in gynecologic cancer. <i>Current Treatment Options in Oncology</i> , <b>2001</b> , 2, 119-28	5.4	2
7	Purification and characterization of a novel 35-kDa protein from transformed cardiomyocytes. <i>Cell Biology International</i> , <b>1999</b> , 23, 299-306	4.5	1
6	Mouse RAD50 has limited epitopic homology to p53 and is expressed in the adult myocardium. <i>Journal of Biological Chemistry</i> , <b>1996</b> , 271, 29255-64	5.4	17
5	Potential approaches for myocardial regeneration. <i>Annals of the New York Academy of Sciences</i> , <b>1995</b> , 752, 446-54	6.5	35
4	Characterization of angiotensin I-converting enzyme (ACE)-containing follicles in the rat ovary during the estrous cycle and effects of ACE inhibitor on ovulation. <i>Endocrinology</i> , <b>1990</b> , 126, 2927-35	4.8	39
3	Evidence for selective expression of angiotensin II receptors on atretic follicles in the rat ovary: an autoradiographic study. <i>Endocrinology</i> , <b>1988</b> , 122, 2727-34	4.8	76

2	Angiotensin II: an intraovarian regulatory peptide. <i>American Journal of the Medical Sciences</i> , <b>1988</b> , 295, 406-8	2.2	46
1	A Pan-Cancer Census of Dominant Tumor Immune Archetypes		3